Jorga Fialova

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Mucopolysaccharidosis type IVA and severe hidradenitis suppurativa: A case series.

Mucopolysaccharidosis type IVA and severe hidradenitis suppurativa: A case series.

Journal: JAAD case reports

Published: August 08, 2025

Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.

Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.

Journal: International journal of dermatology

Published: May 21, 2025

Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry.

Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry.

Journal: Advances in therapy

Published: May 22, 2024

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic.

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic.

Journal: Dermatology and therapy

Published: September 27, 2023

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.

Journal: The Journal of dermatological treatment

Published: May 31, 2022

Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry.

Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry.

Journal: The Journal of dermatological treatment

Published: February 16, 2022

Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.

Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.

Journal: Central European journal of public health

Published: April 20, 2021

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.

Journal: Dermatology and therapy

Published: April 13, 2021

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic.

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic.

Journal: Dermatology and therapy

Published: December 22, 2020

Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic.

Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic.

Journal: Dermatologic therapy

Published: December 05, 2020

Results of Kidney Transplantation from Expanded Criteria Donors: A Single-Center Experience.

Results of Kidney Transplantation from Expanded Criteria Donors: A Single-Center Experience.

Journal: International journal of organ transplantation medicine

Published: March 14, 2018

Flow Cytometry Panel-Reactive Antibody Screening of Anti-HLA Antibodies in the Waiting List Significantly Reduces the Occurrence of Acute Rejection After Kidney Transplantation.

Flow Cytometry Panel-Reactive Antibody Screening of Anti-HLA Antibodies in the Waiting List Significantly Reduces the Occurrence of Acute Rejection After Kidney Transplantation.

Journal: Transplantation proceedings

Published: October 09, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026